This Article Free Full Text (Free PDF) Free References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Cohn, J. N Search for Related Content PubMed PubMed Citation Articles by Cohn, J. N Social Bookmarking                         What's this?

Rationale for angiotensin II receptor blocker therapy in chronic heart failure

University of Minnesota Medical School, Minneapolis, USA

Inhibiting the synthesis of angiotensin II (Ang II) by angiotensin-converting enzyme (ACE) inhibitor treatment has long been established as the recommended therapy for heart failure (HF). As ACE inhibitors are only partially effective in blocking the formation of Ang II, additional treatment with selective Ang II receptor blockers (ARBs) promise additional benefits in patients with HF. This hypothesis is currently being evaluated in Val-HeFT, a large-scale, randomised, double-blind, placebo-controlled study on the effects of adding the highly selective ARB valsartan to usual therapy (diuretics, digoxin, beta-blockers, ACE inhibitors) for HF treatment.

Key Words: congestive heart failure • angiotensin II • combination treatment • angiotensin II receptor blockade • mortality study

Journal of Renin-Angiotensin-Aldosterone System, Vol. 1, No. 2 suppl, S38-S40 (2000)
DOI: 10.3317/jraas.2000.055


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?